	US 12,473,370 B2
	TL1A associated antibody compositions and methods of use
Daniele Biasci, Athens (GR); Sharrol Bachas, Vancouver, WA (US); Amir Shanehsazzadeh, Vancouver, WA (US); Vincent Blay, Vancouver, WA (US); Matthew Waugh, Vancouver, WA (US); Simon Levine-Gottreich, Vancouver, WA (US); Anand Sastry, Vancouver, WA (US); Douglas Ganini Da Silva, Vancouver, WA (US); Matthew McPartlon, Vancouver, WA (US); Emily Gage, Vancouver, WA (US); and David Spencer, Vancouver, WA (US)
Assigned to ABSCI CORPORATION, Vancouver, WA (US)
Filed by ABSCI CORPORATION, Vancouver, WA (US)
Filed on Oct. 2, 2024, as Appl. No. 18/905,034.
Claims priority of provisional application 63/682,593, filed on Aug. 13, 2024.
Claims priority of provisional application 63/675,403, filed on Jul. 25, 2024.
Claims priority of provisional application 63/554,832, filed on Feb. 16, 2024.
Claims priority of provisional application 63/542,186, filed on Oct. 3, 2023.
Prior Publication US 2025/0109210 A1, Apr. 3, 2025
Int. Cl. C07K 16/28 (2006.01); G16B 15/30 (2019.01); G16B 40/00 (2019.01)

CPC C07K 16/2875 (2013.01) [G16B 15/30 (2019.02); G16B 40/00 (2019.02); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

23 Claims

1. An antibody or antigen-binding fragment thereof, comprising:

(a) a variable heavy chain complementarity-determining region CDR-H1, CDR-H2 and CDR-H3, wherein:

i. CDR-H1 comprise the polypeptide sequence of SEQ ID NO: 4,

ii. CDR-H2 comprises the polypeptide sequence of SEQ ID NO: 5,

iii. CDR-H3 comprises the polypeptide sequence of SEQ ID NO: 20; and

(b) a variable light chain complementarity-determining region CDR-L1, CDR-L2 and CDR-L3, wherein

i. CDR-L1 comprises the polypeptide sequence of SEQ ID NO: 19,

ii. CDR-L2 comprises the polypeptide sequence of GAS, and

iii. CDR-L3 comprises the polypeptide sequence of SEQ ID NO: 3.